CSL (ASX:CSL) share price heads lower on haemophilia B deal

The CSL Limited (ASX: CSL) share price lower today despite announcing plans to buy rights for novel late-stage gene therapy candidate.

| More on:
A health worker drug testing in a lab to find 'covid-19 vaccine' representing covid shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is slightly lower today despite announcing plans to buy rights for novel late-stage gene therapy candidate.

In late afternoon trade, the global biotech's shares are swapping hands for $276.06, down 0.5%.

What did CSL announce?

Investors appear unfazed by the company's latest release, sending its shares in negative territory.

According to its release, CSL announced it will push forward with its commercialisation and license agreement with Uniqure NV (NASDAQ: QURE).

Founded in 1998, uniQure is a late-stage gene therapy company that is developing etranacogene dezaparvovec (AMT-061) to treat haemophilia B.

The deal, announced last June will give CSL rights to commercialise and sell AMT-061 if approved.

CSL stated that this could be one of the first gene therapies to provide potentially long-term benefits to patients with haemophilia B.

One dose of AMT-061 has shown to increase Factor IX (FIX) plasma levels to a degree that reduces or eliminates the tendency for bleeding for many years. FIX is the blood-clotting protein lacking in people with haemophilia B.

Should AMT-061's trial be successful, appropriate candidate haemophilia B patients will be able to have a one-time treatment to restore FIX activity to functional levels capable of eliminating the need for frequent and ongoing replacement therapies.

What's in the deal?

Under the terms of the deal, uniQure will receive an upfront cash payment of US$450 million next week. This will be followed by regulatory and commercial sales milestone payments and royalties.

CSL stated that uniQure will conclude its Phase 3 HOPE-B trial and commence manufacturing for an initial commercial supply. In turn, CSL Behring will look after regulatory submissions and commercialisation.

CSL CEO and managing director, Paul Perreault commented:

We are continuing to build on our legacy of delivering lifesaving innovations in haematology with today's news. This agreement enables us to take forward a gene therapy that, if approved, has the potential to transform the lives of haemophilia B patients.

Etranacogene dezaparvovec has the potential to be the first-ever gene therapy approved for haemophilia B and help CSL Behring deliver on our ongoing commitment to improving the lives of those living with haemophilia B.

How has the CSL share price performed lately?

Since early March, CSL shares have begun their accent to levels achieved in mid-January. Year-to-date performance is marginally lower at around 2%, however, it seems the worst is behind the company. Just yesterday, CSL released its presentation for the upcoming Macquarie Group Ltd (ASX: MQG) conference, citing an update on plasma collections.

CSL has a market capitalisation of around $126 billion, with approximately 455.1 million shares on issue.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »